European Patent Office declares CureVac mRNA patent valid
The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 ...
CureVac stock rises on positive patent ruling against BioNTech
Shares of CureVac (NASDAQ: CVAC) climbed 11% following a favorable patent validity decision in its legal proceedings against BioNTech (NASDAQ: NASDAQ: BNTX). The ...
American Association of Individual Investors13h
3 Undervalued Biotechnology Stocks for Thursday, March 27
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...
Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 202 ...
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S.
The key moments that shaped school response to the pandemic
Take a look back on the events that unfolded for educators after COVID-19 was declared a national emergency in March 2020.